NTrans Technologies specializes in non-viral delivery platforms for cell and gene therapies. The company focuses on delivering therapies to specific cells and tissues by leveraging natural mechanisms for cellular uptake.

NTrans Technologies

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Fangliang Zhang

Genscript Biotech Corporation

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

NTrans Technologies BV | 832 followers on LinkedIn. Natural delivery to unlock the full potential of cell and gene therapies | Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues.

We leverage nature’s own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery.

CEO and co-founder of Predica Diagnostics BV

Marco De Boer (Ph.D., MBA)

CEO NTrans Technologies | Innovation Management | Life Sciences

Ester Weijers

Research Technician

Yali Gal-On

Senior Scientist at Ntrans technologies

Camilo F Muñoz Segovia

NTrans Technologies BV

We were honored to welcome the Mayor of Leiden Peter Heijkoop to NTrans Technologies at our location in the Leiden BioScience Park, housed in the vibrant ecosystem of Biopartner. This esteemed visit reinforces the dynamic connections between innovative companies and local leadership within our community. The Mayor’s engagement and enthusiasm for the Leiden BioScience Park is inspiring, showcasing a shared vision for advancing science and innovation in our region. His interest in NTrans Technologies reflects the growing support for groundbreaking research and entrepreneurial spirit in the life sciences sector. During the visit, our CEO Ester Weijers had the opportunity to pitch our latest developments, followed by an insightful lab tour. We appreciated the thought-provoking questions he asked, which truly reflect his commitment to understanding and supporting our field. Thank you to the Mayor for a memorable visit, and for his continued support of innovation in Leiden! #Leiden #LeidenBioSciencePark #Biopartner #NTransTechnologies #Biotech #ResearchAndInnovation #ScientificInnovation #LifeSciences

We are excited to share that EUR 10 million have been awarded to NecstGen , NTrans Technologies BV , Leiden University Medical Center , and Divvly to transform Cell and Gene Therapies through the IPCEI Med4Health program. This significant funding will drive our efforts to transform the production of cell and gene therapies, making these life-saving treatments more accessible and affordable for patients in need. Read more about this collaborative effort here: https://lnkd.in/eaURZiu3 #celltherapy #genetherapy #biotechinnovation #CGT #IPCEI

We are searching for talent! We are currently searching for an enthusiastic research technician - molecular biology to join our team. If you have any questions please don't hesitate to ask. #hiring #HLO #LifeSciences #NTransTechnologies #vacancy #carreers

NTrans Technologies participates in BIO-Europe Spring 2024 on 18-20 March in Barcelona. BIO-Europe Spring 2024 is a key event in making connections and building partnerships in the global biopharma community. NTrans looks forward to engaging in meaningful discussions and establishing new partnerships. NTrans Technologies BV developed a non-viral delivery platform for cell and gene therapies building upon CRISPR technology. With our delivery platform we aim to solve a critical bottleneck: safe and scalable delivery of gene-editing therapies.

We're excited to announce the launch of NTrans Technologies brand-new website and visual identity! At NTrans, we are committed to tackling a critical challenge in cell and gene therapy: delivering the gene-editing complex effectively. We prioritize excellence and innovation in our daily endeavors, so that we can make a positive impact for those living with serious diseases. Discover our latest news and learn more about our innovative delivery platform on https://lnkd.in/d_cTYqEF #NTranstechnologies #Websitelaunch #Healthcare #cellandgenetherapy

Metric
Company Name	NTrans Technologies	CRISPR Biotech Engineering	Genscript Biotech Corporation	Moderna, Inc.
Symbol			1.55K	MRNA
MSH ID	COM:NTRANSTECHNOLOGIES	COM:CRISPR-BTE	COM:GENSCRIPT	COM:MODERNATX
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	NL	GB	CN	US
Stage	Venture Round
Employee Count			6.94K	5.60K
Website	ntranstechnologies.com	crispr-bte.com	genscript.com	modernatx.com
LinkedIn	ntrans-technologies		genscript-corporation
Founders

Metric
Market Cap		2.59B	45.01B
Enterprise Value
Monthly Web Traffic	128
Web Traffic Growth	-0.59
Valuation
Raised Capital	1.60M

Metric
Revenue	839.53M	6.75B
Revenue (LTM)
Revenue (NTM)
Gross Profit	409.55M	2.06B
EBITDA	-356.32M	-3.21B
Operating Income	-415.79M	-4.24B
Net Income	-95.48M	-4.71B
EPS	-0.05	-12.34
Diluted EPS	-0.05	-12.34
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54	0.32
Operating Profit Margin	-0.34	-0.62
EBITDA Margin	-0.42	-0.48
Net Profit Margin	-0.11	-0.69
Return on Equity	-0.07	-0.30
Return on Assets	-0.03	-0.26
Return on Capital Employed	-0.12	-0.28

NTRA

COM:NTRANSTECHNOLOGIES

NTrans Technologies

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.03	-10.50
P/B Ratio	3.40	2.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.56	12.39
EV Multiple	-8.88	-5.48

Metric
Days Sales Outstanding		74.67
Days Payables Outstanding	63.28	31.73
Days Inventory Outstanding	46.00	42.12
Operating Cycle	139.82	73.31
Cash Conversion Cycle	105.90	43.23
Asset Turnover	0.30	0.37

Metric
Operating Cash Flow	-286.91M	-3.12B
Free Cash Flow	-543.41M	-3.83B
Cash Flow to Debt	-0.02	-2.28
Operating Cash Flow/Sales	-0.02	-0.46
Free Cash Flow Yield	-0.09	-0.07

Metric
Cash & Equivalents	1.45B	2.91B
Accounts Receivable		493M
Inventory	53.35M	202M
Goodwill	1.36M	52M
Debt to Capitalization	0.42	0.10
Debt to Assets	0.14	0.07
Current Ratio	3.23	2.46
Quick Ratio	4.65	3.92

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10	0.03
R&D to Revenue	0.62	0.51
SG&A to Revenue	0.29